Sonnet BioTherapeutics releases ‘What This Means’ investor segment

Sonnet BioTherapeutics (SONN) announced the release of a Virtual Investor “What This Means” segment. As part of the segment, Dr. Richard Kenney, CMO discussed its recent update on its SB221 clinical trial including that enrollment of the expansion group using the highest maintenance dose from the monotherapy study has been completed, two of the three patients in the E6 does escalation cohort had partial responses, and this provides an opportunity to study the safety of the combination in a larger population. Sonnet expects to get a preliminary efficacy readout later this year. Additionally, Dr. Kenney discussed adding an E7 cohort using a maintenance dose of 1500 ng/kg to study its safety and effectiveness before proceeding to the randomized Phase 2a portion next year, which will evaluate PROC patients at one of the two highest doses compared to the standard of care, following the dose recommendation from the Safety Review Committee.